Medela Announces NEW Pump In Style Breast Pump

Medela announced the launch of the NEW Pump In Style with MaxFlow Technology double electric, personal-use breast pump in the U.S. and Canada. Featuring a hospital-performance, a closed system and intuitive control panel, Pump In Style combine the trusted performance moms expect from Medela with exclusive new unique technology and modern design.

“Parents today are busy, and even more so in a COVID-19 quarantined world. They balance jobs, childcare, potential homeschooling, and many other responsibilities, and these hardworking parents deserve a simple product that makes their lives easier,” said Melissa Gonzales, executive vice president of the Americas for Medela. “Redefining the breast pump that has supported millions of moms for nearly 25 years, during National Breastfeeding Month in the U.S., is an exciting milestone for Medela and an opportunity to honor moms with a highly effective, high performing and easy-to-use breast pump that works as hard as they do. During these difficult economic times, we wanted to introduce how we’ve reimagined the #1 breast pump chosen by moms and recommended by doctors** to support the breastfeeding families who need to access a high-quality breast pump through insurance, WIC and our retail partners.”

The Hardworking Pump for the Hardworking Mom

The Pump In Style Breast Pump with MaxFlow Technology is designed for moms who pump several times a day and need a highly effective breast pump to maintain their supply. Whether at home or at the office, running errands or enjoying family time, the NEW Pump In Style combines Medela’s deep knowledge and years of research to deliver hospital performance, an easy-to-use interface, comfort, and reassurance.

  • Performance: Innovative vacuum mechanism combines Medela’s research-based 2-Phase Expression® technology with a NEW MaxFlow technology, generating a vacuum with micro-vibrations to increase and optimize milk flow. A clinical pilot study compared MaxFlow technology with standard breast pump technology, revealing that MaxFlow removes a higher percentage of available milk faster than other breast pumps, a significant benefit for moms seeking to build and maintain their milk supply
  • Easy-to-Use Interface: Intuitive controls allow for simple pump operation and easy experience finding Maximum Comfort Vacuum® level. With fewer parts and large openings, it is also easier to clean compared to the previous version
  • Comfort: Two sizes of PersonalFit Flex™ breast shields with soft rim and oval shape for better fit and effective, yet comfortable pumping. The flex shields are another award-winning innovation added to this pump designed to help mom extract 11.8 percent more milk faster
  • Reassurance: Closed system prevents milk from entering the Y-tubing and pump motor, providing confidence in hygiene and quality of expressed milk. The new tube design eliminates tangling issues and simplifies the connection for double or single pumping

To ensure that all moms have access to continue feeding their babies with breast milk for longer, the new Pump In Style with MaxFlow Technology will be available through insurance plans beginning in September. Medela’s new Pump In Style with Max Flow will be available through major distributors that provide breast pumps through insurance, including Aeroflow Breastpumps, Byram Healthcare, Edgepark, and Medline @ Home; additional breast pump distributors will come online in October and November. Families who qualify for the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) will be able to access Pump In Style with MaxFlow technology in October.

The NEW Pump In Style with MaxFlow Technology retails for U.S. $199.99 to $249.99 SRP. It is available now for U.S. shoppers online at Amazon, Target.com, Walmart.com, BuyBuyBaby.com and in-store at Target, and it will be available in Buy Buy Baby Stores in October and at Walmart in November. For Canadian shoppers, the Pump In Style will be available for purchase beginning August 28 on Amazon.ca, Walmart.ca, BabiesRUs.ca and BuyBuyBaby.com, for $375 CDN.

 

SourceMedela

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”